Lynn Dorothy Poulton

This inventor holds 12 USPTO granted patents and 10 published patent applications, plus 1 CIPO patent and 5 EPO patents. Top assignees: Cephalon, Inc., Cephalon Australia Pty. Ltd., Teva Pharmaceuticals Australia Pty Ltd. Active years: 2013-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Lynn Dorothy Poulton. Retrieved from https://idiyas.com/inventor/lynn-dorothy-poulton

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 12 (Patent Applications = 10)

% Patents Active = 91.7

CIPO Patents = 1 (Patent Applications = 4)

EPO Patents = 5 (Patent Applications = 8)

Average Co-Inventor Count = 6.9

ph-index = 4

Forward Citations = 27(Granted Patents)

Location History:

Beecroft, AU (2013)
Macquarie Park, AU (2018 - 2024)

Company Filing History:

Cephalon Australia Pty. Ltd.

patents

1 out of 14

Teva Pharmaceuticals Australia Pty Ltd

patents

Years Active: 2013-2025

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12410256 - Antibodies that specifically bind to TL1a and methods of treating gastrointestinal or lung diseases (2025-09-09),

2. 12410247 - Polynucleotides encoding antibodies that specifically bind to human IL-15 (2025-09-09),

3. 12384841 - Anti-PAR-2 antibodies and methods of use thereof (2025-08-12),

4. 12162946 - Antibodies that specifically bind to TL1A and methods of treating gastrointestinal disease (2024-12-10),

5. 12018084 - Anti-CXCR2 antibodies and uses thereof (2024-06-25),

6. 11725052 - Anti-PAR-2 antibodies and methods of use thereof (2023-08-15),

7. 11332534 - Anti-CXCR2 antibodies and uses thereof (2022-05-17),

8. 11267883 - Antibodies that specifically bind to human IL-15 and uses thereof (2022-03-08),

9. 11220549 - Antibodies that specifically bind to TL1A and methods of treating respiratory tract diseases (2022-01-11),

10. 10822422 - Antibodies against TL1a and uses thereof (2020-11-03),

11. 10138296 - Antibodies that specifically bind to TL1A (2018-11-27),

12. 8563697 - Anti-IL-12/IL-23 antibodies (2013-10-22),

Title: Lynn Dorothy Poulton: Innovator in Antibody Research

Introduction

Lynn Dorothy Poulton is a prominent inventor based in Macquarie Park, Australia. She has made significant contributions to the field of biotechnology, particularly in the development of antibodies for therapeutic applications. With a total of 12 patents to her name, her work has the potential to impact the treatment of various diseases.

Latest Patents

Among her latest patents, Poulton has developed antibodies that specifically bind to TL1a, which are crucial for treating gastrointestinal and lung diseases. This patent discloses TNF-like ligand 1a (TL1a)-binding proteins that inhibit the interaction of TL1a and Death Receptor 3 (DR3), while not affecting the interaction with Decoy Receptor 3 (DcR3). Additionally, she has worked on polynucleotides encoding antibodies that specifically bind to human IL-15. These recombinant antibodies inhibit immune cell proliferation and can be utilized in treating autoimmune or inflammatory diseases, including Celiac disease.

Career Highlights

Poulton has had a successful career, working with notable companies such as Cephalon, Inc. and Cephalon Australia Pty. Ltd. Her expertise in antibody research has positioned her as a leader in her field, contributing to advancements in medical treatments.

Collaborations

Throughout her career, Poulton has collaborated with esteemed colleagues, including Anthony Gerard Doyle and Adam Clarke. These partnerships have fostered innovation and have been instrumental in her research endeavors.

Conclusion

Lynn Dorothy Poulton's contributions to antibody research exemplify her dedication to advancing medical science. Her innovative patents and collaborations highlight her role as a key figure in the biotechnology industry.

Profile summary based on public USPTO records.